Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2333 • 2019 ACR/ARP Annual Meeting
Risk of Incident Myocardial Infarction Among Disabled Patients with Rheumatoid Arthritis Who Were Beneficiaries of the Social Security Disability Insurance
Iris Navarro-Millan¹, Mangala Rajan ¹, Geyanne Lui ¹, Lisa Kern ¹, Laura Pinheiro ¹, Sebastian E. Sattui ², Lisa Mandl ³, Fenglong Xie ⁴, Jeffrey Curtis ⁵ and Monika Safford ¹, ¹Weill Cornell Medicine, New York, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, New York, NY, ⁴University of Alabama at Birmingham, Birmingham, ⁵University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with RA have high risk for myocardial infarction (MI). A meta-analysis showed that the age and sex adjusted pooled relative risk of MI…
Abstract Number: 2358 • 2019 ACR/ARP Annual Meeting
Short-term Risk of Major Adverse Cardiovascular Events or Venous Thrombo-embolic Events in Patients with Rheumatoid Arthritis Initiating a Janus Kinase Inhibitor: A Meta-analysis of Randomised Controlled Trials
Margaux MALAURIE¹, Arnaud Constantin ², Yannick Degboé ¹, Adeline Ruyssen-Witrand ³ and Thomas Barnetche ⁴, ¹CHU TOULOUSE, TOULOUSE, France, ²CHU TOUOUSE, TOULOUSE, France, ³Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ⁴FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France
Background/Purpose: The objective was to investigate the short-term risk of major adverse cardiovascular events (MACEs) or venous thromboembolic events (VTEs) in patients with rheumatoid arhthritis…
Abstract Number: 2384 • 2019 ACR/ARP Annual Meeting
Yoga Improves Fatigue and Mental Health in Rheumatoid Arthritis: Preliminary Results of a Randomized Controlled Trial
Silva Pukšić¹, Joško Mitrović ², Melanie-Ivana Čulo ², Marcela Živković ³, Biserka Orehovec ⁴, Dubravka Bobek ⁵, Marko Lucijanić ⁶ and Jadranka Morović-Vergles ⁷, ¹Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ²Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, Zagreb, Croatia, ³Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁴Department of Laboratory Diagnostics, University Hospital Dubrava, Zagreb, Croatia, ⁵Department of Physical Medicine and Rehabilitation with Rheumatology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁶Department of Hematology, University Hospital Dubrava, Zagreb, Croatia, Zagreb, Croatia, ⁷Department of Clinical Immunology, Rheumatology and Allergology, University Hospital Dubrava, School of Medicine,Zagreb, Croatia, Zagreb, Croatia
Background/Purpose: Rheumatoid arthritis (RA) patients perceive reduced health-related quality of life (HRQOL) through functional disability, pain, increased fatigue and impaired psychological functioning. Previous trials demonstrated…
Abstract Number: 2716 • 2019 ACR/ARP Annual Meeting
Long Term Outcomes of Childhood Onset Rheumatoid Arthritis
Rebecca Overbury¹, Aimee Hersh ², CJ Inman ², Sara Stern ², Karen James ² and John Bohnsack ³, ¹Assisstant Professor, University of Utah, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³University of Utah School of Medicine, Salt Lake City, UT
Background/Purpose: Childhood onset rheumatoid arthritis (CORA) describes patients with juvenile idiopathic arthritis (JIA) who are rheumatoid factor (RF) or anti-cyclic citrullinated antibody (ACPA) positive. Phenotypically,…
Abstract Number: 2852 • 2019 ACR/ARP Annual Meeting
Shared and Differing Risk Factors for PsA, Psoriasis, AS, and RA: A Series of Case-control Studies
Alexis Ogdie¹, Xingmei Wang ¹, Thorvardur J Love ², Telma Thrastardottir ³, Maureen Dubreuil ⁴ and Joel Gelfand ⁵, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ³University of Iceland, Reykjavik, Iceland, ⁴Boston University School of Medicine, Boston, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: While a handful of clinical risk factors for the development of inflammatory diseases have been identified, to date, no studies have compared risk factors…
Abstract Number: 11 • 2019 ACR/ARP Annual Meeting
Biomarker Changes for Patients with Rheumatoid Arthritis Receiving Tofacitinib with Methotrexate or Glucocorticoids vs Tofacitinib Monotherapy
Julie Lee¹, Xing Chen ¹, Weidong Zhang ¹, David Martin ¹, Craig Hyde ¹, Tomohiro Hirose ², Shweta Shah ³ and Lori Fitz ¹, ¹Pfizer Inc, Cambridge, MA, ²Pfizer Japan Inc, Toyko, Japan, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. Herpes zoster (HZ) is more common in patients (pts) with RA vs…
Abstract Number: 97 • 2019 ACR/ARP Annual Meeting
Low Frequency of Circulating T Follicular Helper 1 Cells Is Associated to Adequate Response to Adalimumab Therapy in Rheumatoid Arthritis
Charlotte Lucas¹, Roussine Codo ², Jean-David Albert ³, Rachel Jean ², Stéphane Rodriguez ⁴, Patricia Amé-Thomas ⁵ and Aleth Perdriger ⁶, ¹Rheumatology department, Rennes University Hospital, France, Rennes, Bretagne, France, ²SITI Laboratory, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ³Rheumatology department, Rennes University Hospital and Institut NUMECAN, INSERM U 1241, Rennes, Bretagne, France, ⁴PhD, SITI Laboratory, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ⁵SITI Laboratory, Univ Rennes, Rennes University Hospital, EFS, INSERM1236, France, Rennes, Bretagne, France, ⁶Rheumatology department, Rennes University Hospital, France, Rennes, France
Background/Purpose: T follicular helper cells (Tfh) constitute a distinct CD4+ helper T-cell subset, promoting B-cell maturation and activation. Circulating Tfh (cTfh) seem to play a…
Abstract Number: 190 • 2019 ACR/ARP Annual Meeting
Accuracy of Administrative Algorithms for Identifying Interstitial Lung Disease in Rheumatoid Arthritis
Bryant England¹, Punyasha Roul ², Tina Mahajan ³, Namrata Singh ⁴, Fang Yu ², Harlan Sayles ², Grant Cannon ⁵, Brian Sauer ⁵, Joshua Baker ⁶, Jeffrey Curtis ⁷ and Ted Mikuls ⁸, ¹VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ⁴University of Iowa, Iowa City, ⁵Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ⁶University of Pennsylvania, Philadelphia, PA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) affects 10-15% of RA patients leading to significant disability and premature mortality. While large administrative datasets have been widely leveraged…
Abstract Number: 283 • 2019 ACR/ARP Annual Meeting
Can Synovial Hypertrophy in the Feet Without Doppler Change During Treatment – Results from a Longitudinal Study of Rheumatoid Arthritis Patients Initiating Biological DMARD
Lene Terslev¹, Mikkel Østergaard ², Joe Sexton ³ and Hilde Hammer ⁴, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Copenhagen, Denmark, ²Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ³Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway, ⁴Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway
Background/Purpose: Ultrasound is used to assess disease activity in rheumatoid arthritis (RA). Gray scale (GS) ultrasound shows the synovial hypertrophy (SH) and Doppler the amount…
Abstract Number: 448 • 2019 ACR/ARP Annual Meeting
Central Sensitization in Patients with Rheumatoid Arthritis Using the Central Sensitization Inventory
Kentaro Noda¹, Moe Saitou ¹, Taro Ukichi ¹, Yohsuke Oto ¹, Ken Yoshida ¹ and Daitaro Kurosaka ¹, ¹The Jikei University School of Medicine, Tokyo, Japan
Background/Purpose: Pain of rheumatoid arthritis (RA) is thought to be nociceptive. However, recent studies indicate that RA pain also includes the mechanism of central sensitization…
Abstract Number: 474 • 2019 ACR/ARP Annual Meeting
Associations of Plasma Extravesicular (EV) MicroRNA Levels in Seropositive and Seronegative Rheumatoid Arthritis (RA)
Lissette Delgado-Cruzata ¹, Milena Rodriguez Alvarez ², Nickolas Almodovar³, Toni-Ann Bravo ³ and Shante Hinson ⁴, ¹John Jay College of Criminal Justice, City University of New York, New York, ²SUNY Downstate Medical Center, New York, NY, ³John Jay College of Criminal Justice, City University of New York, New York, NY, ⁴Lincoln Medical & Mental Mental Health Center, New York
Background/Purpose: Rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) are biomarkers that allow early diagnosis of RA in seropositive (ACPA+ or RF+) patients. However, some…
Abstract Number: 525 • 2019 ACR/ARP Annual Meeting
Factors Associated with Persistent Drug-free Remission in Patients with Rheumatoid Arthritis
Larissa Valor¹, Melanie Hagen ², Michaela Reiser ³, Fabian Hartmann ³, Arnd Kleyer ², Bernhard Manger ⁴, Georg Schett ⁵, Jürgen Rech ⁶ and Koray Tascilar ⁷, ¹Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen., Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg. Department of Internal Medicine 3 - Rheumatology and Immunology. Erlangen. Germany., Erlangen, Germany, ⁵Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ⁶Department of Internal Medicine 3, Friedrich-Alexander-University Erlangen-Nuremberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, University Hospital Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany
Background/Purpose: Persistent drug-free remission of RA is a condition close to “cure” of the disease. Long-term drug-free remission is considered rare and challenging to reach,…
Abstract Number: 820 • 2019 ACR/ARP Annual Meeting
Diurnal Stability of Transcriptional Profiles in Rheumatoid Arthritis
Louise Bennett¹, Fraser Morton ¹, George Fragoulis ¹, Caron Paterson ¹, Dominic Rimmer ², Gary Semple ³, Alison Young ³, Jagtar S Nijjar ⁴, Michael Barrett ⁵, Stefan Siebert ¹, Duncan Porter ⁵, Carl Goodyear ⁶ and Iain McInnes ¹, ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Clinical Research Facility, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom, ³Clinical Research Facility, NHS Greater Glasgow and Clyde, Glasgow, ⁴Department of Medicine, University of Cambridge, Cambridge, United Kingdom, ⁵Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, ⁶University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Our understanding of disease pathogenesis in Rheumatoid Arthritis (RA) is rapidly expanding with the advent of ‘Omics’ techniques. Importantly, current analysis takes into account…
Abstract Number: 927 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Filgotinib for Patients with Rheumatoid Arthritis Naïve to Methotrexate Therapy: FINCH3 Primary Outcome Results
Rene Westhovens¹, William F.C. Rigby ², Désirée van der Heijde ³, Daniel W.T. Ching ⁴, Beatrix Bartok ⁵, Franziska Matzkies ⁵, Zhaoyu Yin ⁵, Ying Guo ⁵, Chantal Tasset ⁶, John Sundy ⁵, Neelufar Mozaffarian ⁵, Osvaldo Daniel Messina ⁷, Robert B.M. Landewé ⁸, Tatsuya Atsumi ⁹ and Gerd Burmester ¹⁰, ¹University Hospitals, Leuven, Belgium, ²Dartmouth College, Lebanon, NH, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Timaru Hospital, Timaru, New Zealand, ⁵Gilead Sciences, Inc., Foster City, CA, ⁶Galapagos NV, Mechelen, Belgium, ⁷Cosme Argerich Hospital and IRO Medical Center, Buenos Aires, Argentina, ⁸Amsterdam University Medical Center, Amsterdam, Netherlands, ⁹Hokkaido University, Sapporo, Japan, ¹⁰Charité—University Medicine Berlin, Berlin, Germany
Background/Purpose: Filgotinib (FIL), an orally administered, potent, selective inhibitor of Janus kinase 1 (JAK1), has shown good efficacy and was well tolerated for treatment of…
Abstract Number: 1135 • 2019 ACR/ARP Annual Meeting
Optimizing the Management of Flares in Patients with Rheumatoid Arthritis with the Help of Non-Physician Providers: Results of a Randomized Controlled Trial
Elena Myasoedova¹, Cynthia Crowson ², Rachel Giblon ¹, Kathleen McCarthy-Fruin ¹, Daniel Schaffer ¹, Kerry Wright ¹, Eric Matteson ³ and John Davis ¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester, Rochester, ³Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester
Background/Purpose: Flares in rheumatoid arthritis (RA) are common. The shortage of readily available specialized care may hinder early detection and timely management of RA flares.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.